Cardiff Oncology Analyst Ratings
Cardiff Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 728.03% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/09/2023 | 791.72% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 03/29/2023 | 855.41% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/07/2023 | 855.41% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 09/16/2022 | 791.72% | HC Wainwright & Co. | $22 → $14 | Maintains | Buy |
| 09/13/2022 | 218.47% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 08/29/2022 | 282.17% | Baird | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 1301.27% | HC Wainwright & Co. | $25 → $22 | Maintains | Buy |
| 02/28/2022 | 1492.36% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 12/08/2021 | 1110.19% | Baird | → $19 | Initiates Coverage On | → Outperform |
| 08/10/2021 | 1556.05% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 05/10/2021 | 1492.36% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 10/22/2020 | 1619.75% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 10/08/2020 | 1492.36% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 09/18/2020 | 791.72% | Maxim Group | $6 → $14 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/08/2023 | 728.03% | HC Wainwright & Co. | 14 美元 → 13 美元 | 維護 | 購買 |
| 05/09/2023 | 791.72% | HC Wainwright & Co. | 15 美元 → 14 美元 | 維護 | 購買 |
| 03/29/2023 | 855.41% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 03/07/2023 | 855.41% | HC Wainwright & Co. | 14 美元 → 15 美元 | 維護 | 購買 |
| 2022 年 9 月 16 日 | 791.72% | HC Wainwright & Co. | 22 美元 → 14 美元 | 維護 | 購買 |
| 09/13/2022 | 218.47% | 派珀·桑德勒 | 7 美元 → 5 美元 | 維護 | 超重 |
| 08/29/2022 | 282.17% | 貝爾德 | 9 美元 → 6 美元 | 維護 | 跑贏大盤 |
| 05/09/2022 | 1301.27% | HC Wainwright & Co. | 25 美元 → 22 美元 | 維護 | 購買 |
| 02/28/2022 | 1492.36% | HC Wainwright & Co. | 26 美元 → 25 美元 | 維護 | 購買 |
| 2021 年 8 月 12 日 | 1110.19% | 貝爾德 | → 19 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 10 月 8 日 | 1556.05% | HC Wainwright & Co. | 25 美元 → 26 美元 | 維護 | 購買 |
| 2021 年 10 月 5 日 | 1492.36% | HC Wainwright & Co. | 27 美元 → 25 美元 | 維護 | 購買 |
| 2020 年 10 月 22 日 | 1619.75% | HC Wainwright & Co. | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 8 月 10 日 | 1492.36% | 派珀·桑德勒 | → 25 美元 | 啓動覆蓋開啓 | → 超重 |
| 09/18/2020 | 791.72% | Maxim 集團 | 6 美元 → 14 美元 | 維護 | 購買 |
What is the target price for Cardiff Oncology (CRDF)?
加的夫腫瘤學（CRDF）的目標價格是多少？
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $13.00 expecting CRDF to rise to within 12 months (a possible 728.03% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月8日公佈了加的夫腫瘤學（納斯達克股票代碼：CRDF）的最新目標股價。這家分析公司將目標股價定爲13.00美元，預計CRDF將在12個月內升至12個月內（可能上漲728.03％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
分析師對加的夫腫瘤學（CRDF）的最新評級是多少？
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
加的夫腫瘤學（納斯達克股票代碼：CRDF）的最新分析師評級由HC Wainwright & Co. 提供，Cardiff Oncology 維持買入評級。
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Cardiff Oncology（CRDF）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究，包括瀏覽公開財務報表、與Cardiff Oncology的高管和客戶交談以及聽取業績電話會議後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Cardiff Oncology 的最後評級是在2023年8月8日提交的，因此您應該預計下一個評級將在2024年8月8日左右公佈。
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
分析師對加的夫腫瘤學 (CRDF) 的評級是否正確？
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $14.00 to $13.00. The current price Cardiff Oncology (CRDF) is trading at is $1.57, which is out of the analyst's predicted range.
雖然評級是主觀的，將會發生變化，但最新的加的夫腫瘤學（CRDF）評級維持不變，目標股價爲14.00美元至13.00美元。Cardiff Oncology（CRDF）目前的交易價格爲1.57美元，超出了分析師的預測區間。